VP, Pharmaceutical Operations & Qualified Pharmacist Christophe Ancel joined Transgene in 2008, first as Head of Quality Assurance and then as Vice President, Operational Quality. Prior to that, he was a consultant for several international pharmaceutical groups. From 2001 to 2005, he was Head of Quality, Assistant Pharmacist and Interim Responsible Pharmacist for the… Continue reading Christophe ANCEL
Year: 2021
Transgene presents data from Phase I clinical trial confirming the potential of the oncolytic virus TG6002
Transgene presents data from Phase I clinical trial confirming the potential of the oncolytic virus TG6002
produits : BT-001
BT-001 BT-001 is a multifunctional oncolytic virus encoding for an anti-CTLA4 antibody and GM-CSF BT-001 is the first oncolytic virus from Invir.IO® and is optimized to act as a Trojan horse. Two specific “weapons” have been integrated into the Vaccinia viral DNA: an anti-CTLA4 antibody, which was developed by BioInvent, and the cytokine GM-CSF, which… Continue reading produits : BT-001
produits : TG6002
TG6002 TG6002, multifunctional oncolytic virus A new generation of multifunctional oncolytic virus, TG6002 has been designed to combine the mechanism of oncolysis (targeted destruction of the cancer cell) with the production of chemotherapy (5-FU), directly into the tumor. TG6002 aims to attack solid tumors on multiple “fronts” while avoiding the side effects of chemotherapy. This… Continue reading produits : TG6002
produits : TG4001
TG4001 TG4001 is a therapeutic vaccine designed to express HPV-16 antigens TG4001 is an innovative therapy capable of combating papillomavirus-induced cancers. The concept behind TG4001 is to teach the immune system to recognise and destroy the cancer cells expressing HPV-16 antigens, specifically E6 and E7 antigens. TG4001 is being evaluated in a Phase II study… Continue reading produits : TG4001
Transgene Announces Upcoming Investor Meetings
Transgene Announces Upcoming Investor Meetings
Annual General Meeting
Annual General Meeting of May 15, 2024 2024 ORDINARY AND EXTRAORDINARY MEETING Location TRANSGENE 400 boulevard Gonthier d’Andernach – Parc d’Innovation 67400 ILLKIRCH-GRAFFENSTADEN – FRANCE Date and Time 15 May 2024 at 10 am Documents Notice of the 2022 General Shareholder’s Meeting / BALO (in French) Notice of meeting Voting formular Universal Registration Document 2022 Information… Continue reading Annual General Meeting
CORPORATE GOVERNANCE
Transgene complies with the corporate governance recommendations of the MiddleNext Code of Governance for Mid and Small Caps (the Code) (Code de gouvernement d’entreprise des valeurs moyennes et petites de MiddleNext). MiddleNext is an independent society representing midcap public issuers; the Code is largely referred to by small, mid and even large cap firms and… Continue reading CORPORATE GOVERNANCE
événements et presentations
Corporate presentation Webcasts Financial calendar Investor events
Analysts
Company Analyst E-mail Phone Cantor Fitzgerald Brandon Folkes brandon.folkes@cantor.com +1 212-294-8081 Intron Health Naresh Chouhan naresh@intronhealthresearch.com +44 207 375 9143 Invest Securities Jamila El Bougrini jelbougrini@invest-securities.com +33 (0)1 44 88 88 09 Kempen & Co. Suzanne van Voorthuizen suzanne.vanvoorthuizen@kempen.com +31 (0)20 348 8484 Oddo BHF Martial Descoutures martial.descoutures@oddo-bhf.com +33 (0)1 44 51 85 00 Any… Continue reading Analysts
